IL143485A0 - Non-myeloablative tolerogenic treatment - Google Patents

Non-myeloablative tolerogenic treatment

Info

Publication number
IL143485A0
IL143485A0 IL14348599A IL14348599A IL143485A0 IL 143485 A0 IL143485 A0 IL 143485A0 IL 14348599 A IL14348599 A IL 14348599A IL 14348599 A IL14348599 A IL 14348599A IL 143485 A0 IL143485 A0 IL 143485A0
Authority
IL
Israel
Prior art keywords
tolerogenic treatment
myeloablative
myeloablative tolerogenic
treatment
tolerogenic
Prior art date
Application number
IL14348599A
Other languages
English (en)
Original Assignee
Hadasit Med Res Service
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service, Baxter Int filed Critical Hadasit Med Res Service
Publication of IL143485A0 publication Critical patent/IL143485A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14348599A 1998-12-31 1999-12-23 Non-myeloablative tolerogenic treatment IL143485A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/222,011 US6428782B1 (en) 1997-05-23 1998-12-31 Non-myeloablative tolerogenic treatment
PCT/US1999/030704 WO2000040701A2 (en) 1998-12-31 1999-12-23 Non-myeloablative tolerogenic treatment

Publications (1)

Publication Number Publication Date
IL143485A0 true IL143485A0 (en) 2002-04-21

Family

ID=22830367

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14348599A IL143485A0 (en) 1998-12-31 1999-12-23 Non-myeloablative tolerogenic treatment

Country Status (6)

Country Link
US (1) US6428782B1 (xx)
EP (3) EP1498479A2 (xx)
JP (1) JP2002534083A (xx)
CA (1) CA2356434A1 (xx)
IL (1) IL143485A0 (xx)
WO (1) WO2000040701A2 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
JP3734461B2 (ja) 2001-08-08 2006-01-11 松下電器産業株式会社 ライセンス情報変換装置
WO2003038048A2 (en) * 2001-10-30 2003-05-08 The United States Of America As Represented By The Secretary Of The Navy Ex-vivo rescue of transplantable hematopoietic stem cells following myeloablative injury
AU2002952834A0 (en) * 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
WO2005021734A2 (en) * 2003-09-02 2005-03-10 University Of Massachussets Generation of hematopoietic chimerism and induction of central tolerance
CN101583273A (zh) * 2005-07-22 2009-11-18 加利福尼亚大学董事会 肝素组合物和选择素抑制
CA2631760A1 (en) * 2005-12-02 2007-06-07 Robert A. Brodsky Use of high-dose oxazaphosphorine drugs for treating immune disorders
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273738A (en) 1990-03-03 1993-12-28 Fred Hutchinson Cancer Research Center Radiation delivery to lymphoid and marrow tissues
ES2172514T3 (es) 1992-01-08 2002-10-01 Gen Hospital Corp Tolerancia inducida a los xenoinjertos.
US5876708A (en) * 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US5589582A (en) 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
AU7404494A (en) 1993-07-21 1995-02-20 Cellpro, Incorporated Methods and compositions for preventing immune rejection of solid organ grafts
ES2143553T3 (es) * 1993-09-02 2000-05-16 Dartmouth College Anticuerpos anti-gp39 y sus utilizaciones.
US5514364A (en) 1993-09-13 1996-05-07 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5635156A (en) 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
IL112969A (en) * 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
WO1996031229A1 (en) * 1995-04-05 1996-10-10 Beth Israel Hospital Association Inhibiting rejection of a graft
CA2220971A1 (en) 1995-05-25 1996-11-28 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
WO1998020932A2 (en) * 1996-11-15 1998-05-22 Baxter International Inc. Conditioning for allogeneic stem cell transplantation
MXPA99010587A (es) * 1997-05-23 2005-01-10 Hadasit Med Res Service Tratamiento tolerogenico no mieloablativo.

Also Published As

Publication number Publication date
JP2002534083A (ja) 2002-10-15
EP1498136A2 (en) 2005-01-19
US6428782B1 (en) 2002-08-06
WO2000040701A9 (en) 2001-09-13
EP1498136A8 (en) 2005-04-13
WO2000040701A2 (en) 2000-07-13
EP1498479A2 (en) 2005-01-19
CA2356434A1 (en) 2000-07-13
WO2000040701A3 (en) 2000-12-21
EP1141246A2 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
GB2321193B (en) Endoscopic treatment tool
ZA978450B (en) Medical treatment
GB9804885D0 (en) Therapeutic combination
GB9700899D0 (en) Novel treatment
GB9800942D0 (en) Well treatment
IL143485A0 (en) Non-myeloablative tolerogenic treatment
ZA978359B (en) Novel treatment
GB9615767D0 (en) Novel treatment
GB9608657D0 (en) Novel treatment
IL132845A0 (en) Non-myeloablative tolerogenic treatment
GB0020261D0 (en) Therapeutic treatment
GB9815497D0 (en) Treatment
GB9818524D0 (en) Inorgasmia treatment
GB9625795D0 (en) Novel treatment
GB9828550D0 (en) Treatment
GB9721692D0 (en) Novel treatment
GB9612752D0 (en) Novel treatment
GB9716742D0 (en) Treatment
GB9812914D0 (en) Treatment
GB9804442D0 (en) Novel treatment
GB9617762D0 (en) Treatment
GB9721693D0 (en) Novel treatment
GB9614751D0 (en) Novel treatment
GB9616407D0 (en) Novel treatment
GB9604046D0 (en) Novel treatment

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees